Functional dyspepsia: modern pathogenetic aspects and therapeutic approaches

Functional  dyspepsia, affecting  up to 20% of individuals worldwide, remains  both a cause  of decreased activity of patients’ daily life and an obvious economic burden  due to healthcare costs. Despite extensive research, the etiology of dyspepsia  is unknown  in most  patients. Intestinal motility dysfunction  has long been  considered the  major culprit, but recent  studies suggest  that  immune  pathophysiological and molecular  effects  in the  duodenum are far more likely predisposing factors. Eosinophilia  and an increase  in mast  cells in both  the  duodenum and gastric mucosa  are identified  in most patients with this disease. More and more data  on the significant  role of impaired  paracellular permeability of the intestinal mucosa are now available. It is associated with subclinical  inflammation in the submucosal layer in patients with functional  dyspepsia. This explains  the  poor effectiveness of the  treatments taken. The evidence  from practice  suggests that  symptoms  persist or return  after  eradication therapy  in most patients. Proton  pump inhibitors  and antidepressants do not ease  postprandial distress  syndrome.  Montelukast  and  cromolyn  therapy  has  been  proposed,  but  this  approach  is not  yet  widely popular. Therefore, there  is an obvious need  in finding other  therapeutic approaches. One of them  is the increased use of prokinetics, the most recent  of which is acotiamide.  Its mechanism  of action  is similar to that  of prior generation prokinetics  (inhibition of acetylcholinesterase activity), but is distinguished by the absence of impact on dopaminergy, due to which the drug has  far fewer  side  effects. In addition,  its effect  on the  production  of ghrelin, which physiological  role  is being  actively studied, is discussed.

1. Stanghellini V, Chan FK, Hasler WL, Malagelada JR, Suzuki H, Tack J, Talley NJ. Gastroduodenal Disorders. Gastroenterology. 2016;150(6):1380–1392. https://doi.org/10.1053/j.gastro.2016.02.011.

2. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130(5):1480–1491. https://doi.org/10.1053/j.gastro.2005.11.061.

3. Drossman DA, Hasler WL. Rome IV-Functional GI Disorders: Disorders of Gut-Brain Interaction. Gastroenterology. 2016;150(6):1257–1261. https://doi.org/10.1053/j.gastro.2016.03.035.

4. Enck P, Azpiroz F, Boeckxstaens G, Elsenbruch S, Feinle-Bisset C, Holtmann G et al. Functional dyspepsia. Nat Rev Dis Primers. 2017;3:17081. https://doi.org/10.1038/nrdp.2017.81.

5. Adibi P, Keshteli AH, Daghaghzadeh H, Roohafza H, Pournaghshband N, Afshar H. Association of anxiety, depression, and psychological distress in people with and without functional dyspepsia. Adv Biomed Res. 2016;5:195. https://doi.org/10.4103/2277-9175.190936.

6. Rodrigues DM, Motomura DI, Tripp DA, Beyak MJ. Are psychological interventions effective in treating functional dyspepsia? A systematic review and meta-analysis. J Gastroenterol Hepatol. 2021;36(8):2047–2057. https://doi.org/10.1111/jgh.15566.

7. Esterita T, Dewi Sh, Suryatenggara FG, Glenardi G. Association of Functional Dyspepsia with Depression and Anxiety: A Systematic Review. J Gastrointe­ stin Liver Dis. 2021;30(2):259–266. https://doi.org/10.15403/jgld-3325.

8. Tack J, Piessevaux H, Coulie B, Caenepeel P, Janssens J. Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology. 1998;115(6):1346–1352. https://doi.org/10.1016/s0016-5085(98)70012-5.

9. Ochoa-Cortes F, Turco F, Linan-Rico A, Soghomonyan S, Whitaker E, Wehner S et al. Enteric Glial Cells: A New Frontier in Neurogastroenterology and Clinical Target for Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2016;22(2):433–449. https://doi.org/10.1097/MIB.0000000000000667.

10. Ruhl A. Glial cells in the gut. Neurogastroenterol Motil. 2005;17(6):777–790. https://doi.org/10.1111/j.1365-2982.2005.00687.x.

11. Tominaga K, Fujikawa Y, Tanaka F, Kamata N, Yamagami H, Tanigawa T et al. Structural changes in gastric glial cells and delayed gastric emptying as responses to early life stress and acute adulthood stress in rats. Life Sci. 2016;148:254–259. https://doi.org/10.1016/j.lfs.2016.02.025.

12. Lee HS, Kim D-K, Kim YB, Lee KJ. Effect of acute stress on immune cell counts and the expression of tight junction proteins in the duodenal mucosa of rats. Gut Liver. 2013;7(2):190–196. https://doi.org/10.5009/gnl.2013.7.2.190.

13. Jung HK, Talley NJ. Role of the Duodenum in the Pathogenesis of Functional Dyspepsia: A Paradigm Shift. J Neurogastroenterol Motil. 2018;24(3):345–354. https://doi.org/10.5056/jnm18060.

14. Vanheel H, Vicario M, Vanuytsel T, Oudenhove LV, Martinez C, Keita ÅV et al. Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia. Gut. 2014;63(2):262–271. https://doi.org/10.1136/gutjnl-2012-303857.

15. Cirillo C, Bessissow T, Desmet A-S, Vanheel H, Tack J, Berghe PV. Evidence for neuronal and structural changes in submucous ganglia of patients with functional dyspepsia. Am J Gastroenterol. 2015;110(8):1205–1215. https://doi.org/10.1038/ajg.2015.158.

16. Tanaka F, Tominaga K, Fujikawa Y, Nagami Y, Kamata N, Yamagamiet H et al. Concentration of Glial Cell Line-Derived Neurotrophic Factor Positively Correlates with Symptoms in Functional Dyspepsia. Dig Dis Sci. 2016;61(12):3478–3485. https://doi.org/10.1007/s10620-016-4329-5.

17. Du L, Chen B, Kim J, Chen X, Dai N. Micro-inflammation in functional dyspepsia: A systematic review and meta-analysis. Neurogastroenterol Motil. 2018;30(4):e13304. https://doi.org/10.1111/nmo.13304.

18. Talley N, Walker M, Aro P, Ronkainen J, Storskrubb T, Hindley L et al. Non-ulcer dyspepsia and duodenal eosinophilia: an adult endoscopic population-based case-control study. Clin Gastroenterol Hepatol. 2007;5(10):1175–1183. https://doi.org/10.1016/j.cgh.2007.05.01.

19. Du L, Shen J, Kim J, Yunxian Y, Ma L, Dai N. Increased Duodenal Eosinophil Degranulation in Patients with Functional Dyspepsia: A Prospective Study. Sci Rep. 2016;6:34305. https://doi.org/10.1038/srep34305.

20. Walker M, Aggarwal K, Shim L, Bassan M, Kalantar J, Weltman M et al. Duodenal eosinophilia and early satiety in functional dyspepsia: confirmation of a positive association in an Australian cohort. J Gastroenterol Hepatol. 2014;29(3):474–479. https://doi.org/10.1111/jgh.12419.

21. Date Y, Kojima M, Hosoda H, Sawaguchi A, Mondal M, Suganuma T et al. Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology. 2000;141:4255–4261. https://doi.org/10.1210/endo.141.11.7757.

22. Vasyukova ОV, Vitebskaya AV. Grelin: biological significance and prospects for use in endocrinology. Problemy Endokrinologii. 2006;52(2):3–7. (In Russ.) https://doi.org/10.14341/probl20065223-7.

23. Fuglsang J, Skjaerbaek C, Espelund U, Frystyk J, Fisker S, Flyvbjerg A, Ovesen P. Ghrelin and its relationship to growth hormones during normal pregnancy. Clin Endocrinol (Oxf). 2005;62(5):554–559. https://doi.org/10.1111/j.1365-2265.2005.02257.x.

24. Kheradmand A, Alirezaei M, Asadian P, Rafiei Alavi E, Joorabi S. Antioxidant enzyme activity and MDA level in the rat testis following chronic administration of ghrelin. Andrologia. 2009;41(6):335–340. https://doi.org/10.1111/j.1439-0272.2009.00932.x.

25. Shindo T, Futagami S, Hiratsuka T, Horie A, Hamamoto T, Ueki N et al. Comparison of gastric emptying and plasma ghrelin levels in patients with functional dyspepsia and non-erosive reflux disease. Digestion. 2009;79(2):65–72. https://doi.org/10.1159/000205740.

26. Fukui H, Xu X, Miwa H. Role of Gut Microbiota-Gut Hormone Axis in the Pathophysiology of Functional Gastrointestinal Disorders. J Neurogastroenterol Motil. 2018;24(3):367–386. https://doi.org/10.5056/jnm1807.

27. Park MI. Is There Enough Evidence for the Association of GNbeta3 C825T Polymorphism With Functional Dyspepsia and Irritable Bowel Syndrome? J Neurogastroenterol Motil. 2012;18(3):348–349. https://doi.org/10.5056/jnm.2012.18.3.348.

28. Zhao B, Zhao J, Cheng W-F, Shi W-J, Liu W, Pan X-L, Zhang G-X. Efficacy of Helicobacter pylori eradication therapy on functional dyspepsia: a meta-analysis of randomized controlled studies with 12-month follow-up. J Clin Gastroenterol. 2014;48:241–247. https://doi.org/10.1097/MCG.0b013e31829f2e25.

29. Madisch A, Andresen V, Enck P, Labenz J, Frieling T, Schemann M. The Diagnosis and Treatment of Functional Dyspepsia. Dtsch Arztebl Int. 2018;115(13):222–232. https://doi.org/10.3238/arztebl.2018.0222.

30. Malfertheiner P, Megraud F, O’Morain C, Atherton J, Axon AT, Bazzoli F et al. Management of Helicobacter pylori infection – the Maastricht IV / Florence Consensus Report. Gut. 2012;61:646–664. https://doi.org/10.1136/gutjnl-2012-302084.

31. Wang W, Huang J, Zheng G, Xia H, Wong W, Liu X et al. Effects of proton-pump inhibitors on functional dyspepsia: a meta-analysis of randomized placebo-controlled trials. Clin Gastroenterol Hepatol. 2007;5:178–185. https://doi.org/10.1016/j.cgh.2006.09.012.

32. Ivashkin VT, Mayev IV, Sheptulin AA, Lapina TL, Trukhmanov AS, Kartavenko IM et al. Diagnosis and treatment of the functional dyspepsia: clinical guidelines of the Russian Gastroenterological Association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(1):50–61. (In Russ.) https://doi.org/10.22416/1382-4376-2017-27-1-50-61.

33. Ford A, Luthra P, Tack J, Boeckxstaens G, Moayyedi P, Talley N. Efficacy of psychotropic drugs in functional dyspepsia: systematic review and meta-analysis. Gut. 2017;66:410–420. https://doi.org/10.1136/gutjnl-2015-310721.

34. Talley N, Locke G, Saito Y, Almazar A, Bouras E, Howden C et al. Effect of amitriptyline and escitalopram on functional dyspepsia: A multicenter, randomized controlled study. Gastroenterology. 2015;149:340–349. https://doi.org/10.1053/j.gastro.2015.04.020.

35. Melzer J, Rösch W, Reichling J, Brignoli R, Saller R. Meta-analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5. Aliment Pharmacol Ther. 2004;20:1279–1287. https://doi.org/10.1111/j.1365-2036.2004.02275.x.

36. Friesen C, Kearns G, Andre L, Neustrom M, Roberts C, Abdel-Rahman S. Clinical efficacy and pharmacokinetics of montelukast in dyspeptic children with duodenal eosinophilia. J Pediatr Gastroenterol Nutr. 2004;38(3):343–351. https://doi.org/10.1097/00005176-200403000-00021.

37. Friesen C, Neilan N, Schurman J, Taylor D, Kearns G, Abdel-Rahman S. Montelukast in the treatment of duodenal eosinophilia in children with dyspepsia: effect on eosinophil density and activation in relation to pharmacokinetics. BMC Gastroenterol. 2009;9:32. https://doi.org/10.1186/1471-230X-9-32.

38. Friesen C, Sandridge L, Andre L, Roberts C, Abdel-Rahman S. Mucosal eosinophilia and response to H1/H2 antagonist and cromolyn therapy in pediatric dyspepsia. Clin Pediatr (Phila). 2006;45(2):143–147. https://doi.org/10.1177/000992280604500205.

39. Friesen CA, Schurman JV, Colombo JM, Abdel-Rahman SM. Eosinophils and mast cells as therapeutic targets in pediatric functional dyspepsia. World J Gastrointest Pharmacol Ther. 2013;4(4):86–96. https://doi.org/10.4292/wjgpt.v4.i4.86.

40. Talley NJ. Functional dyspepsia: Advances in diagnosis and therapy. Gut and Liver. 2017;3:349–357. https://doi.org/10.5009/gnl16055.

41. Huang X, Lv B, Zhang S, Fan Y-H, Meng L-N. Itopride therapy for functional dyspepsia: a meta-analysis. World J Gastroenterol. 2012;18(48):7371–7377. https://doi.org/10.3748/wjg.v18.i48.7371.

42. Ueda M, Iwasaki E, Suzuki H. Profile of acotiamide in the treatment of functional dyspepsia. Clin Exp Gastroenterol. 2016;9:83–88. https://doi.org/10.2147/CEG.S72172.

43. Miwa H, Nagahara A, Asakawa A, Arai M, Oshima T, Kasugai K et al. Evidence-based clinical practice guidelines for functional dyspepsia. J Gastroenterol. 2022;57(2):47–61. https://doi.org/10.1007/s00535-021-01843-7.

44. Kusunoki H, Haruma K, Manabe N, Imamura H, Kamada T, Shiotani A et al. Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: randomized controlled study evaluation by real-time ultrasonography. Neurogastroenterol Motil. 2012;24(6):540–545. https://doi.org/10.1111/j.1365-2982.2012.01897.x.

45. Seto K, Sasaki T, Katsunuma K, Kobayashi N, Tanaka K, Tack J. Acotiamide hydrochloride (Z-338), a novel prokinetic agent, restores delayed gastric emptying and feeding inhibition induced by restraint stress in rats. Neurogastroenterol Motil. 2008;20(9):1051–1059. https://doi.org/10.1111/j.1365-2982.2008.01135.x.

46. Yamawaki H, Futagami S, Kawagoe T, Maruki Y, Hashimoto S, Nagoya H et al. Improvement of meal-related symptoms and epigastric pain in patients with functional dyspepsia treated with acotiamide was associated with acylated ghrelin levels in Japan. Neurogastroenterol Motil. 2016;28(7):1037–1047. https://doi.org/10.1111/nmo.12805.

47. Matsueda K, Hongo M, Tack J, Saito Y, Kato H. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut. 2012;61(6):821–828. https://doi.org/10.1136/gutjnl-2011-301454.

48. Shinozaki S, Osawa H, Sakamoto H, Hayashi Y, Kawarai Lefor A, Yamamoto H. The effect of acotiamide on epigastric pain syndrome and postprandial distress syndrome in patients with functional dyspepsia. J Med Invest. 2016;63(3.4):230–235. https://doi.org/10.2152/jmi.63.230.

49. Mayanagi S, Kishino M, Kitagawa Y, Sunamura M. Efficacy of acotiamide in combination with esomeprazole for functional dyspepsia refractory to proton-pump inhibitor monotherapy. Tohoku J Exp Med. 2014;234(3):237–240. https://doi.org/10.1620/tjem.234.237.

50. Bakulin IG, Khlynov IB, Sablin OA, Pakhomova IG, Pavlova NV. Clinical efficacy of acotiamide in patients with functional dyspepsia: results of a multicenter study. Meditsinskiy Sovet. 2023;(13):108–115. (In Russ.) https://doi.org/10.21518/ms2023-253.